Skip to main content
Zhejiang Ausun Pharmaceutical Co., Ltd. logo

Zhejiang Ausun Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 603229 ISIN · CNE100002XK2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 991 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603229

About Zhejiang Ausun Pharmaceutical Co., Ltd.

https://www.ausunpharm.com/

Zhejiang Ausun Pharmaceutical Co., Ltd. is a research-driven pharmaceutical enterprise specializing in the development, manufacturing, and global distribution of high-quality Active Pharmaceutical Ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas including antiviral, cardiovascular, central nervous system, and anti-inflammatory treatments. Its product portfolio features key APIs such as Entecavir, Tenofovir, and Ezetimibe, produced under stringent international quality standards including US FDA, EU GMP, and EDQM certifications. Ausun Pharmaceutical leverages advanced chemical synthesis and biotechnology platforms to provide integrated CDMO services and innovative drug solutions. By maintaining a robust R&D pipeline and state-of-the-art production facilities, the company serves a diverse global clientele, emphasizing technical excellence and regulatory compliance in the pharmaceutical supply chain.

Recent filings

Filing Released Lang Actions
奥翔药业2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm on the convening, procedures, attendance, agenda and voting results of the company’s 2025 Annual General Meeting. It is not the AGM presentation itself (IP/AGM-R) nor a standalone vote-results notice stripped of legal analysis (DVA). Rather, it is a compliance/legal opinion filed with regulators and the exchange. It does not contain substantive financial statements or management discussion, so it’s not an annual/interim report. Nor is it a proxy statement or other specific category. Therefore, it falls under the general “Regulatory Filings” fallback category (RNS).
2026-05-20 Chinese
奥翔药业关于参股公司在香港联合交易所主板挂牌上市的公告
Capital/Financing Update Classification · 82% confidence The document is an official company announcement concerning its affiliate (a subsidiary) listing on the Hong Kong Stock Exchange, including details of the global public issuance of new H shares and the company’s shareholding. This is a corporate finance event (share issuance and listing). It does not represent an AGM packet, earnings release, board change, or statutory report filing, but rather an update on capital markets activity. Therefore it fits best under Capital/Financing Update (CAP).
2026-05-13 Chinese
奥翔药业2025年年度股东会会议资料
AGM Information Classification · 92% confidence The document is titled “2025年年度股东会会议资料” and contains the agenda, rules, and proposals for the 2025 Annual General Meeting, including meeting time, venue, voting procedures, and seven resolution proposals to be deliberated by shareholders. It is clearly materials distributed for the AGM rather than a standalone financial report or announcement. Therefore, it falls under “AGM Information” (Code: AGM-R).
2026-05-11 Chinese
奥翔药业关于使用部分闲置募集资金临时补充流动资金的公告
Capital/Financing Update Classification · 85% confidence The document is a regulatory announcement by a listed company detailing the plan to use idle proceeds from a previous non-public share issuance to temporarily supplement working capital. It describes the amounts raised, the prior uses, the new usage plan, approval by the board, and compliance with fundraising regulations. This is not an earnings release, financial report, or share issuance, but rather an update on the use of financing proceeds. The best fit is “Capital/Financing Update” (CAP).
2026-04-28 Chinese
奥翔药业关于2026年度开展外汇衍生品交易的公告
Regulatory Filings Classification · 78% confidence The document is a formal announcement by Zhejiang Aoxiang Pharmaceuticals regarding its plan to undertake foreign exchange derivative transactions for hedging purposes in 2026. It details transaction purpose, amounts, procedures, risks, and accounting treatment, but it is not a financial report (e.g., annual, interim), earnings release, M&A announcement, capital restructuring, director dealing, or other specific categories. This type of board disclosure of pending derivative transactions falls under general regulatory announcements. Therefore, it best fits the Regulatory Filings category (RNS).
2026-04-28 Chinese
奥翔药业2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 75% confidence The document is a standalone evaluation report titled “2025年度会计师事务所履职情况评估报告,” detailing the company’s assessment of its appointed audit firm’s qualifications, independence, and performance in auditing the 2025 financial statements. It is not an Annual Report (10-K) or mere announcement; it is audit‐related content outside the full audit opinion itself but clearly falls under audit information. Therefore, it best matches the Audit Report / Information category (AR).
2026-04-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.